Immunotherapy Combinations with Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions

Seminars in Oncology

Volumn 42, Issue , 2015, Pages S12-S19

  Atkins, Michael ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TALIMOGENE LAHERPAREPVEC; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER SIZE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; METASTATIC MELANOMA; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; CELL CYCLE CHECKPOINT; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; MULTIMODALITY CANCER THERAPY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CELL CYCLE CHECKPOINTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA; TREATMENT OUTCOME;

EID: 84947757513     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.10.002     Document Type: Review

References (40)

1. S.L. Topalian, C.G. Drake, and D.M. Pardoll Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 2015 450 461
2. M.A. Postow, M.F. Callahan, and J.D. Wolchok Immune checkpoint blockade in cancer therapy J Clin Oncol 33 2015 1974 1982
3. M.A. Postow, J. Chesney, A.C. Pavlick, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2015 2006 2017
4. T. Okazaki, S. Chikuma, Y. Iwai, S. Fagarasan, and T. Honjo A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application Nat Immunol 14 2013 1212 1218
5. P. Sharma, and J.P. Allison The future of immune checkpoint therapy Science 348 2015 56 61
6. P. Sharma, and J.P. Allison Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential Cell 161 2015 205 214
7. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
8. M. Aris, and M.M. Barrio Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment Front Immunol 6 2015 46
9. Leach DR, Krummel MF, Allison JP. Enhancement of anti-tumor immunity by CTLA-4 blockade. Science. 1996;271:1734-1736.
10. H. Dong, S.E. Strome, D.R. Salomao, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
11. A.M. Curran, W. Montalvo, H. Yahita, and Allison JP PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci U S A 107 2010 4275 4280
12. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
13. M. Ai, and M.A. Curran Immune checkpoint combinations from mouse to man Cancer Immunol Immunother 64 2015 885 892
14. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 1999 141 151
15. H. Nishimura, T. Okazaki, Y. Tanaka, and et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice Science 291 2001 319 322
16. P. Waterhouse, J.M. Penninger, E. Timms, and et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 Science 270 1995 985 988
17. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 2015 23 34
18. J.D. Wolchok, V. Chiarion-Sileni, R. Gonzalez, and et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067) [abstract] J Clin Oncol (Meeting Abstracts) 2015 33 LBA1
19. M. Sznol, H. Kluger, M.K. Callahan, and et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) [abstract] J Clin Oncol (Meeting Abstracts) 2014 32 LBA9003
20. Kluger H., Sznol M., Callahan M., et al. Survival, response duration, and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma [abstract]. Ann Oncol (Meeting Abstracts). 2014;25 suppl 4:iv374-iv393.
21. M.B. Atkins Melanoma therapy: yet another breakthrough May 29-June 2, 2015 Presented at 2015 American Society of Clinical Oncology Chicago, IL Session discussion
22. C. Robert, J. Schachter, G.V. Long, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2015 2521 2532
23. A. Ribas, I. Puzanov, T.F. Gajewski, and et al. A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage 3b-4 melanoma [abstract] J Clin Oncol (Meeting Abstracts) 33 2015 9081
24. B.L. Liu, M. Robinson, Z.Q. Han, and et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumor properties Gene Ther 10 2003 292 303
25. I. Puzanov, M. Milhem, R.H. Andtbacka, and et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma [abstract] J Clin Oncol (Meeting Abstracts) 33 2015 9063
26. A. Ribas, F.S. Hodi, M. Callahan, C. Kontu, and J. Wolchok Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 2013 1365 1366
27. I. Puzanov, M.K. Callahan, G.P. Linette, and et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 2511
28. J.C. Hassel, S. Lee, F. Meiss, and et al. Vemurafenib and ipilimumab: a promising approach [abstract]? J Clin Oncol (Meeting Abstracts) 33 2015 e20075
29. A. Ribas, M. Butler, J. Lutzky, and et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma [abstract] J Clin Oncol (Meeting Abstracts) 33 2015 3003
30. J. Weber, O. Hamid, A. Amin, and et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma Cancer Immun 13 2013 1 9
31. C. Robert, L. Thomas, I. Bondarenko, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
32. K.M. Koller, H.B. Mackley, H. Wagner, and et al. Concurrent ipilimumab and radiotherapy in patients with metastatic melanoma: a retrospective analysis [abstract] J Clin Oncol (Meeting Abstract) 33 2015 e20048
33. M.A. Postow, M.K. Callahan, C.A. Barker, and et al. Immunologic correlates of the abscopal effect in a patient with melanoma N Engl J Med 366 2012 925 931
34. E.B. Golden, S. Demaria, P.B. Schiff, A. Chachoua, and S.C. Formenti An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer Cancer Immunol Res 1 2013 365 372
35. A.M. Grimaldi, E. Simeone, D. Giannarelli, and et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy Oncoimmunology 3 2014 e28780
36. C.A. Barker, M.A. Postow, S.A. Khan, and et al. Concurrent radiotherapy and ipilimumab immunotherapy in patients with melanoma Cancer Immunol Res 1 2013 92 98
37. D.S. Chen, and I. Mellman Oncology meets immunology: the cancer immunity cycle Immunity 39 2013 1 10
38. J.J. Luke, H. Donahue, M. Nishino, and et al. Clinical experience and correlates of ipilimumab 3 mg/kg with GM-CSF in advanced melanoma [abstract] J Clin Oncol (Meeting Abstracts) 33 2015 e20025
39. F.S. Hodi, S. Lee, D.F. McDermott, and et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial JAMA 312 2014 1744 1753
40. D.M. Pardoll Immunology beats cancer: a blueprint for successful translation Nat Immunol 12 2012 1129 1132